Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SangStat Med. (SANG) - 10 of 10 analysts say Strong Buy -- Ignore unavailable to you. Want to Upgrade?

To: John S. Sturges who wrote (80)	2/16/1998 11:06:00 PM
From: James Silverman	Respond to of 184

I'd suggest everyone do their own homework on PDLI/SANG. Mr. Sturges, for whatever reason, has taken it upon himself to shamelessly hype PDLI, passing along erroneous information again and again on several different message boards. Again John, transplant patients receive a cocktail of drugs. Cyclosporine is the anchor of these combos. Zenapax is approved in combo with cyclosporine. Zenapax is not a potential replacement to cyclosporine, now or in the future. A _very niche_use of cyclosporine is in treating the most serious cases of uveitis, where loss of sight is a risk. For the most part, uveitis is treated effectively with eyedrops or corticosteroids. Mr. Sturges has claimed zenapax will replace cyclosporine in transplant surgery, this could not be further from the truth. If Mr. Sturges would take 5 minutes out of his day as a broker at CIBC Oppenheimer to call PDLI he would soon realize how far off based his beliefs are. Of course I believe Mr. Sturges has been intentionally deceptive, strange behavior for a 50 year old broker at a well established and respected firm. Jim